Literature DB >> 727322

Humoral immune responses in human hepatosplenic schistosomiasis mansoni.

R W Goodgame, D G Colley, C C Draper, F A Lewis, M L McLaren, R P Pelley.   

Abstract

The development of hepatosplenic schistosomiasis in humans cannot always be related to the intensity of infection. A study was designed to identify different humoral immunologic responses to Schistosoma mansoni in patients with and without hepatosplenic disease. Twenty-four patients with active hepatosplenic disease were closely matched for age, sex, and fecal egg counts with twenty-four patients with only intestinal disease. A serum sample from each of these patients was tested for antibodies to the major soluble egg antigen (MSA1) by radioimmunoassay, for total and IgM antibodies to egg and worm antigenic preparations by ELISA, and for its ability to suppress antigen stimulated lymphocyte blastogenesis. No difference was found using these assays between the hepatosplenic and the intestinal schistosomiasis patients.

Entities:  

Mesh:

Year:  1978        PMID: 727322     DOI: 10.4269/ajtmh.1978.27.1174

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  4 in total

1.  Immunoaffinity fractionation of Schistosoma mansoni worm antigens using human antibodies and its application for serodiagnosis.

Authors:  F N Boctor; H I Shaheen
Journal:  Immunology       Date:  1986-04       Impact factor: 7.397

2.  A histopathological and histochemical study of the ovaries of mice experimentally infected with Schistosoma mansoni.

Authors:  H Abaza; L Asser; S M Abdel Reheim; N Shaaban; S K Marei; M A Hagras
Journal:  Br J Exp Pathol       Date:  1983-02

Review 3.  Immunopathology of Schistosoma mansoni infection.

Authors:  D L Boros
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

4.  Collaborative study on antigens for immunodiagnosis of schistosomiasis.

Authors:  K E Mott; H Dixon
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.